Chondrosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Chondrosarcoma is a rare malignant tumor that forms a cartilaginous matrix. Chondrosarcomas arising de novo are termed primary chondrosarcomas, while those developing in pre-existing benign cartilaginous tumors such as osteochondroma or enchondroma are referred to as secondary chondrosarcomas. CHS constitutes various groups of malignant bone tumors and encompasses multiple histological subtypes. Overall, conventional CHS is the most common subtype. It accounts for 85% of CHS, followed by dedifferentiated (10%), mesenchymal and clear cell CHS, these two representing less than 2% of all CHS cases. Conventional CHS can develop de novo or in a pre-existing enchondroma and osteochondroma. CHS is classified into three grades based on cellular atypia, mitotic figures, and cellularity. CHS grades 1 and 2 are represented by 85% of all CHSs, 15% of cases are grade 3, and the dedifferentiated CHS. According to the latest WHO recommendations, CHS should be classified into central or secondary peripheral atypical cartilaginous tumor/CHS (grade 1), central or secondary peripheral CHS grade 2 and 3.

·       The estimated overall Chondrosarcoma incidence is 1 per 200,000/year and accounts for 20–30% of primary malignant bone tumors. The majority of cases occur after age 50, with a slight male predominance. The incidence of pediatric chondrosarcoma is less than 10% of all chondrosarcoma cases, with higher survival rates than adults.

 

Thelansis’s “Chondrosarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chondrosarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Chondrosarcoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chondrosarcoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Chondrosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Chondrosarcoma, Chondrosarcoma market outlook, Chondrosarcoma competitive landscape, Chondrosarcoma market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033